News & Events
- February 16, 2023
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
- February 14, 2023
Entera Bio to Participate in the SVB Securities Global Biopharma
Conference
- October 6, 2022
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
- September 21, 2022
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
- September 12, 2022
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
- September 12, 2022
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
- September 9, 2022
Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact
- August 11, 2022
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
- July 26, 2022
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
- July 18, 2022
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
- June 17, 2022
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
- May 16, 2022
by WildWeb